These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 28315122)

  • 1. Cardio-oncology: the Nuclear Option.
    Alvarez JA; Russell RR
    Curr Cardiol Rep; 2017 Apr; 19(4):31. PubMed ID: 28315122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart failure and chemotherapeutic agents.
    Piper S; McDonagh T
    Future Cardiol; 2015 Jul; 11(4):453-70. PubMed ID: 26234158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
    Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
    Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
    Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.
    Jain D; Russell RR; Schwartz RG; Panjrath GS; Aronow W
    Curr Cardiol Rep; 2017 May; 19(5):36. PubMed ID: 28374177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity.
    de Geus-Oei LF; Mavinkurve-Groothuis AM; Bellersen L; Gotthardt M; Oyen WJ; Kapusta L; van Laarhoven HW
    J Nucl Med; 2011 Apr; 52(4):560-71. PubMed ID: 21421717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively.
    Schwartz RG; Jain D; Storozynsky E
    J Nucl Cardiol; 2013 Jun; 20(3):443-64. PubMed ID: 23572315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Heart Failure in Cancer Patients and Cancer Survivors.
    Finet JE
    Heart Fail Clin; 2017 Apr; 13(2):253-288. PubMed ID: 28279414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab Cardiotoxicity After Anthracycline Exposure Constitutes a Complex and Clinically Important Entity.
    Ewer MS; Ewer SM
    JACC Heart Fail; 2019 Sep; 7(9):805-807. PubMed ID: 31401098
    [No Abstract]   [Full Text] [Related]  

  • 10. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
    Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
    Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy.
    Abu-Khalaf MM; Safonov A; Stratton J; Wang S; Hatzis C; Park E; Pusztai L; Gross CP; Russell R
    Breast Cancer Res Treat; 2019 Jul; 176(2):261-270. PubMed ID: 31020471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy.
    Bottinor WJ; Migliore CK; Lenneman CA; Stoddard MF
    Curr Cardiol Rep; 2016 Oct; 18(10):99. PubMed ID: 27566332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.
    Gavila J; Seguí MÁ; Calvo L; López T; Alonso JJ; Farto M; Sánchez-de la Rosa R
    Clin Transl Oncol; 2017 Jan; 19(1):91-104. PubMed ID: 27101413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?
    Levis BE; Binkley PF; Shapiro CL
    Lancet Oncol; 2017 Aug; 18(8):e445-e456. PubMed ID: 28759384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology.
    Kostakou PM; Kouris NT; Kostopoulos VS; Damaskos DS; Olympios CD
    Heart Fail Rev; 2019 Jan; 24(1):91-100. PubMed ID: 30073443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on Incorporating Biomarkers with Imaging Findings for the Detection and Management of Cardiotoxicity.
    Quatromoni N; Scherrer-Crosbie M
    Curr Cardiol Rep; 2018 Jun; 20(8):67. PubMed ID: 29931487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.
    Menna P; Minotti G; Salvatorelli E
    Curr Cardiol Rep; 2019 Mar; 21(5):33. PubMed ID: 30887161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear cardio-oncology: From its foundation to its future.
    Kahanda MG; Hanson CA; Patterson B; Bourque JM
    J Nucl Cardiol; 2020 Apr; 27(2):511-518. PubMed ID: 30788760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
    Matos E; Jug B; Blagus R; Zakotnik B
    Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
    Saganelidze K; Kavtaradze N
    Georgian Med News; 2018 May; (278):87-93. PubMed ID: 29905551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.